Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Cingulate Inc.
organization2 mentionslast seen Nov 13, 2026
Biopharmaceutical company developing drug delivery technologies and pharmaceutical products for ADHD and anxiety disorders.
Relationships 8
- Cingulate Inc.developsCTx-130199% confidence2 sources
- Cingulate Inc.developsPrecision Timed Release99% confidence2 sources
- Cingulate Inc.employsShane J. Schaffer99% confidence2 sources
- Cingulate Inc.employsJennifer L. Callahan97% confidence1 source
- Cingulate Inc.employsBryan Downey96% confidence1 source
- Bend BiosciencesuppliesCingulate Inc.93% confidence1 source
- Cingulate Inc.partners withIndegene90% confidence1 source
- Lincoln Park Capitalinvests inCingulate Inc.85% confidence1 source
Relationship
Cingulate Inc.developsCTx-1301
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 13, 2026Cingulate Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.02: Results of Operations and Financial Condition; Item 9.01: Financial Statements and Exhibits
CTx-1301 (dexmethylphenidate HCl) is a once-daily, multi-core tablet utilizing Cingulate's proprietary Precision Timed Release™ (PTR™) platform
- filingSEC EDGARNov 10, 2026Cingulate Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
CTx-1301(dexmethylphenidate HCl), the company's lead asset